If you have been reading about pentadecapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-14. Numbers and descriptions here follow the published literature rather than marketing material.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Vascular shunt A vascular shunt can also bypass the capillary bed and provide a route for blood supply directly to a collecting venule. This is achieved by a metarteriole that supplies around a hundred capillaries. At their junctions are precapillary sphincters that tightly regulate the flow of blood into the capillary bed. When all of the sphincters are closed blood can flow from a metarteriole into a thoroughfare channel and into a collecting venule bypassing the capillary bed.
=== Patent history === The U.S. Food and Drug Administration (FDA) approved tramadol in March 1995, and an extended-release (ER) formulation in September 2005. ER Tramadol was protected by US patents nos. 6,254,887 and 7,074,430. The FDA listed the patents' expiration as 10 May 2014. However, in August 2009, the US District Court for the District of Delaware ruled the patents invalid, a decision upheld the following year by the Court of Appeals for the Federal Circuit. Manufacture and distribution of generic equivalents of Ultram ER in the United States was therefore permitted before the expiration of the patents.
Dinosaur evolution after the Triassic followed changes in vegetation and the location of continents. In the Late Triassic and Early Jurassic, the continents were connected as the single landmass Pangaea, and there was a worldwide dinosaur fauna mostly composed of coelophysoid carnivores and early sauropodomorph herbivores. Gymnosperm plants (particularly conifers), a potential food source, radiated in the Late Triassic. Early sauropodomorphs did not have sophisticated mechanisms for processing food in the mouth, and so must have employed other means of breaking down food farther along the digestive tract. The general homogeneity of dinosaurian faunas continued into the Middle and Late Jurassic, where most localities had predators consisting of ceratosaurians, megalosauroids, and allosauroids, and herbivores consisting of stegosaurian ornithischians and large sauropods. Examples of this include the Morrison Formation of North America and Tendaguru Beds of Tanzania. Dinosaurs in China show some differences, with specialized metriacanthosaurid theropods and unusual, long-necked sauropods like Mamenchisaurus. Ankylosaurians and ornithopods were also becoming more common, but primitive sauropodomorphs had become extinct. Conifers and pteridophytes were the most common plants. Sauropods, like earlier sauropodomorphs, were not oral processors, but ornithischians were evolving various means of dealing with food in the mouth, including potential cheek-like organs to keep food in the mouth, and jaw motions to grind food.
=== 1.3 === DisplayPort version 1.3 was approved on 15 September 2014. This standard increases overall transmission bandwidth to 32.4 Gbit/s with the new HBR3 mode featuring 8.1 Gbit/s per lane (up from 5.4 Gbit/s with HBR2 in version 1.2), for a total data throughput of 25.92 Gbit/s after factoring in 8b/10b encoding overhead. This bandwidth is enough for a 4K UHD display (3840 × 2160) at 120 Hz with 24 bit/px RGB color, a 5K display (5120 × 2880) at 60 Hz with 30 bit/px RGB color, or an 8K UHD display (7680 × 4320) at 30 Hz with 24 bit/px RGB color. Using Multi-Stream Transport (MST), a DisplayPort port can drive two 4K UHD (3840 × 2160) displays at 60 Hz, or up to four WQXGA (2560 × 1600) displays at 60 Hz with 24 bit/px RGB color. The new standard includes mandatory Dual-mode for DVI and HDMI adapters, implementing the HDMI 2.0 standard and HDCP 2.2 content protection. The Thunderbolt 3 connection standard was originally to include DisplayPort 1.3 capability, but the final release ended up with only version 1.2 for Intel 6000 Series Thunderbolt 3 Controllers. Later Intel 7000 Series Thunderbolt 3 controllers support DisplayPort 1.4 capability including HDR. The VESA's Adaptive Sync feature in DisplayPort version 1.3 remains an optional part of the specification.
Sources: en.wikipedia.org
With the exception of Russia, the Polish nation has the distinction among other Slavic peoples of having enjoyed independence as a part of various entities for several centuries prior to the advent of Pan-Slavism. After 1795, Revolutionary and Napoleonic France had influenced many Poles who sought the reconstitution of their existing country—particularly since France was a mutual enemy of Austria, Prussia, and also Russia. Russia's Pan-Slavic rhetoric had alarmed the Poles. Pan-Slavism was not fully embraced among Poles after the early period. Poland did nevertheless express solidarity with those of its fellow Slavic nations that had suffered oppression and were seeking independence. While Pan-Slavism as an ideology was inimical to Austro-Hungarian interests, Poles instead embraced the wide autonomy within the state and assumed a loyalist position towards the Habsburgs. Within the Austro-Hungarian polity, they were able to develop their national culture and preserve the Polish language, both of which were under threat in both German and Russian Empires. A Pan-Slavic federation was proposed, but on the condition that the Russian Empire would be excluded from such an entity. After Poland regained its independence (from Germany, Austria and Russia) in 1918, no internal faction considered Pan-Slavism as a serious alternative, viewing Pan-Slavism as Russification. During Poland's communist era, the USSR used Pan-Slavism as a propaganda tool to justify its control over the country.
=== Linear trap and triple quadrupole === The combination of triple quadrupole MS with LIT technology in the form of an instrument of configuration QqLIT, using axial ejection, is particularly interesting, because this instrument retains the classical triple quadrupole scan functions such as selected reaction monitoring (SRM), product ion (PI), neutral loss (NL) and precursor ion (PC) while also providing access to sensitive ion trap experiments. For small molecules, quantitative and qualitative analysis can be performed using the same instrument. In addition, for peptide analysis, the enhanced multiply charged (EMC) scan allows an increase in selectivity, while the time-delayed fragmentation (TDF) scan provides additional structural information. In the case of the QqLIT, the uniqueness of the instrument is that the same mass analyzer Q3 can be run in two different modes. This allows very powerful scan combinations when performing information-dependent data acquisition.
Gingras has published > 200 articles that have been cited > 35,000 times (Google Scholar; Feb 2020). In 2011, Gingras was named one of Canada's Top 100 Most Powerful Women. In 2015, Gingras was elected a fellow of the Royal Society of Canada. Her work on interaction proteomics, was awarded, alongside John Yates, the Discovery Award in Proteomics from the Human Proteome Organization (2019). She also received the Jeanne Manery Fisher Memorial Lecture award at the 2019 meeting of the Canadian Society for Molecular Biosciences.
Sources: en.wikipedia.org
Primary hypolactasia Primary hypolactasia, or primary lactase deficiency, is genetic, develops in childhood at various ages, and is caused by the absence of a lactase persistence allele. In individuals without the lactase persistence allele, less lactase is produced by the body over time, leading to hypolactasia in adulthood. The frequency of lactase persistence, which allows lactose tolerance, varies enormously worldwide, with the highest prevalence in Northwestern Europe, declines across southern Europe and the Middle East and is low in Asia and most of Africa, although it is common in pastoralist populations from Africa. Secondary hypolactasia Secondary hypolactasia or secondary lactase deficiency, also called acquired hypolactasia or acquired lactase deficiency, is caused by an injury to the small intestine. This form of lactose intolerance can occur in both infants and lactase persistent adults and is generally reversible. It may be caused by acute gastroenteritis, celiac disease, Crohn's disease, ulcerative colitis, chemotherapy, intestinal parasites (such as giardia), or other environmental causes. Primary congenital alactasia Primary congenital alactasia, also called congenital lactase deficiency, is an extremely rare, autosomal recessive enzyme defect that prevents lactase expression from birth. People with congenital lactase deficiency cannot digest lactose from birth, so cannot digest breast milk. This genetic defect is characterized by a complete lack of lactase (alactasia). About 40 cases have been reported worldwide, mainly limited to Finland.
== Structural studies == As of late 2007, 7 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1VLP, PDB: 1YBE, PDB: 1YIR, PDB: 1YTD, PDB: 1YTE, PDB: 1YTK, and PDB: 2F7F.
=== Complications === Complications may include urinary retention, recurring urinary tract infections and incontinence. The anterior vaginal wall may protrude though the vaginal introitus (opening). This can interfere with sexual activity. Recurrent urinary tract infections are common for those who have urinary retention. In addition, though cystocele can be treated, some treatments may not alleviate troubling symptoms, and further treatment may need to be performed. Cystoceles may affect the quality of life; women who have cystoceles tend to avoid leaving their homes and avoid social situations. The resulting incontinence puts women at risk of being placed in a nursing home or long-term care facility.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.